Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 5/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 5/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | F10 | P00742 | 1/20 | 0.64 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.64 |
| ▸ | PDE4A | P27815 | 2/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimobendan SCHEMBL2466855 | 0.92 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL27623 | 0.92 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL29386190 | 0.92 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL14815175 | 0.92 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL15617988 | 0.92 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1996787 | 0.91 | PDE3B (0.83) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL668129 | 0.91 | PDE3B (0.83) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1997246 | 0.90 | PDE3B (0.81) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1993626 | 0.87 | PDE3B (0.77) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL9781456 | 0.87 | PDE3B (0.77) | PDE3BPDE3AABCB11MAOAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2825159-B1 | PHARMACEUTICAL TABLET FORMULATION FOR THE VETERINARY MEDICAL SECTOR, METHOD OF PRODUCTION AND USE THEREOF | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-06-22 | — | — | EP | claimed |
| EP-1176960-B1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-09-29 | — | — | EP | claimed |
| EP-0330052-B1 | Use of benzimidazoles for preparing a medicine with an anti-ischemial activity on the heart, and combinations with betablockers or bradycardics | THOMAE GMBH DR K (DE) | 1993-12-15 | — | — | EP | claimed |
| JP-11092377-A | — | — | None | — | — | JP | disclosed |
| JP-1254627-A | — | — | None | — | — | JP | disclosed |
| EP-4676590-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | Zoetis Services LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025095107-A1 | METHOD FOR PRODUCING PLATEABLE HEPATOCYTES AND APPLICATION THEREOF | 公立大学法人名古屋市立大学 | 2025-05-08 | — | — | WO | disclosed |
| WO-2025018366-A1 | METHOD FOR PRODUCING INTESTINAL EPITHELIAL CELLS | 公立大学法人名古屋市立大学 | 2025-01-23 | — | — | WO | disclosed |
| US-12134784-B2 | Method for preparing intestinal tract cell layer derived from pluripotent stem cell | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2024-11-05 | — | — | US | disclosed |
| US-20240308973-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | ZOETIS SERVICES LLC | 2024-09-19 | — | — | US | disclosed |
| WO-2024191714-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | ZOETIS SERVICES LLC (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-1123703-A1 | IMMUNOMODULATORY DRUG COMPOSITION | Matsumori, Akira (JP) | 2001-08-16 | — | — | EP | disclosed |
| US-5981470-A | ADMINISTERING PHARMACEUTICAL AGENT SELECTED FROM THE GROUP CONSISTING OF AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR, AN ANGIOTENSIN II-RECEPTOR ANTAGONIST, A RENIN INHIBITOR, AND AN ANGIOTENSIN II-RECEPTOR EXPRESSION INHIBITOR | THE UNIVERSITY OF BIRMINGHAM (GB) | 1999-11-09 | — | — | US | disclosed |
| JP-H1192377-A | PHARMACEUTICAL COMPOSITION FOR IMMUNOREGULATION | NIPPON BOEHRINGER INGELHEIM CO LTD | 1999-04-06 | — | — | JP | disclosed |
| US-5401738-A | Angiotensin antagonist, hypotensive, aldosteronism, cardiac insufficiency | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER (DE) | 1995-03-28 | — | — | US | disclosed |
| EP-0574787-A2 | Benzimidazole derivatives as angiotensin II antagonists | MERCK PATENT GmbH (DE) | 1993-12-22 | — | — | EP | disclosed |
| EP-0330052-B1 | Use of benzimidazoles for preparing a medicine with an anti-ischemial activity on the heart, and combinations with betablockers or bradycardics | THOMAE GMBH DR K (DE) | 1993-12-15 | — | — | EP | disclosed |
| EP-0387762-A2 | Medicament with positive inotropic activity, containing a synergistically active mixture consisting of a benzimidazole and a beta-blocker, its preparation and use | Dr. Karl Thomae GmbH (DE) | 1990-09-19 | — | — | EP | disclosed |
| JP-H01254627-A | MEDICINAL COMPOSITION | DR KARL THOMAE GMBH | 1989-10-11 | — | — | JP | disclosed |
| EP-0330052-A2 | Use of benzimidazoles for preparing a medicine with an anti-ischemial activity on the heart, and combinations with betablockers or bradycardics | Dr. Karl Thomae GmbH (DE) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308973-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | PDE3A, PDE3B, PDE5A | PDE3B 2/4885PDE3A 1/4885ABCB11 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.